A possible relationship of natural killer T cells with humoral immune response to 23-valent pneumococcal polysaccharide vaccine in clinical settings

被引:7
|
作者
Miyasaka, Tomomitsu
Aoyagi, Tetsuji [2 ]
Uchiyama, Binei [3 ]
Oishi, Kazunori [4 ]
Nakayama, Toshinori [5 ]
Kinjo, Yuki [6 ]
Miyazaki, Yoshitsugu [6 ]
Kunishima, Hiroyuki [2 ]
Hirakata, Yoichi [2 ]
Kaku, Mitsuo [2 ]
Kawakami, Kazuyoshi [1 ]
机构
[1] Tohoku Univ, Grad Sch Med, Dept Med Microbiol Mycol & Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan
[2] Tohoku Univ, Grad Sch Med, Dept Infect Control & Lab Diagnost, Sendai, Miyagi 9808575, Japan
[3] Katta Gen Hosp, Div Resp Dis, Shiroishi, Miyagi, Japan
[4] Osaka Univ, Microbial Dis Res Inst, Dept Special Pathogens, Lab Clin Res Infect Dis, Suita, Osaka 565, Japan
[5] Chiba Univ, Grad Sch Med, Dept Med Immunol, Chiba, Japan
[6] Natl Inst Infect Dis, Dept Chemotherapy & Mycoses, Tokyo, Japan
关键词
Pneumococcal polysaccharide vaccine; Antibody production; NKT cells; CD1D-RESTRICTED NKT CELLS; STREPTOCOCCUS-PNEUMONIAE; PANDEMIC INFLUENZA; BACTEREMIA; ACTIVATION; INDUCTION; ANTIGENS; ANTIBODY; SUBSETS; MODEL;
D O I
10.1016/j.vaccine.2012.03.007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Pneumococcal polysaccharide vaccine (PPV), a type-2 thymus-independent antigen, induces the activation of B cells by directly triggering their antigen receptors. Although this type of antigen generally does not undergo class switching from IgM to IgG, PPV has been known to induce IgG2 in vaccinated subjects, which suggests the possible involvement of certain innate immune lymphocytes supporting the activation of B cells and their class switching. In the present study, we addressed the possibility that natural killer (NK) T cells are involved in Ab production caused by PPV. We measured serum levels of IgG against pneumococcal capsular polysaccharides and the numbers of CD4(+), CD8(+) and CD4(-)CD8(-) double negative (ON) invariant NKT (iNKT) cells and CD3(+)CD56(+) NKT cells in the peripheral blood before and after PPV injection. IgG was increased after PPV injection, peaking at 4 weeks after injection in serotypes 6B, 19F and 23F and at 3 months in serotype 14. Low responders, whose serum concentrations of IgG peaked at less than double their original levels, constituted 16%, 13%, 13% and 16% of vaccinated subjects with regard to serotypes 613, 14, 19F and 23F, respectively. A significant positive correlation was detected between an increase in ON iNKT cells and the elevation of anti-serotype 14 IgG; in serotype 19F, DN iNKT cells were more markedly increased in responders than in low responders. These results suggest that DN iNKT cells may be involved in IgG production caused by vaccination against pneumococcal capsular polysaccharides. (c) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3304 / 3310
页数:7
相关论文
共 50 条
  • [41] Relationship between asthma status and antibody response pattern to 23-valent pneumococcal vaccination
    Sheen, Youn H.
    Kizilbash, Sarah
    Ryoo, Eell
    Wi, Chung-Il
    Park, Miguel
    Abraham, Roshini S.
    Ryu, Euijung
    Divekar, Rohit
    Juhn, Young
    JOURNAL OF ASTHMA, 2020, 57 (04) : 381 - 390
  • [42] The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial
    Izumi, Yasumori
    Akazawa, Manabu
    Akeda, Yukihiro
    Tohma, Shigeto
    Hirano, Fuminori
    Ideguchi, Haruko
    Matsumura, Ryutaro
    Miyamura, Tomoya
    Mori, Shunsuke
    Fukui, Takahiro
    Iwanaga, Nozomi
    Jiuchi, Yuka
    Kozuru, Hideko
    Tsutani, Hiroshi
    Saisyo, Kouichirou
    Sugiyama, Takao
    Suenaga, Yasuo
    Okada, Yasumasa
    Katayama, Masao
    Ichikawa, Kenji
    Furukawa, Hiroshi
    Kawakami, Kenji
    Oishi, Kazunori
    Migita, Kiyoshi
    ARTHRITIS RESEARCH & THERAPY, 2017, 19
  • [43] Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: A matched case-control study
    Vila-Corcoles, Angel
    Salsench, Elisabet
    Rodriguez-Blanco, Teresa
    Ochoa-Gondar, Olga
    de Diego, Cinta
    Valdivieso, Amparo
    Hospital, Imma
    Gomez-Bertomeu, Frederic
    Raga, Xavier
    VACCINE, 2009, 27 (10) : 1504 - 1510
  • [44] Evaluation of effectiveness, safety and cost-benefit of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-Infected patients
    Zou, Xiaobai
    He, Jianmei
    Zheng, Jun
    Liang, Mengran
    Gao, Jinjin
    Huang, Jianwen
    Jiang, Yang
    Jiang, Yonglin
    Chen, Xi
    VACCINE, 2022, 40 (01) : 37 - 42
  • [45] Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users
    Amendola, A
    Tanzi, E
    Zappa, A
    Colzani, D
    Boschini, A
    Musher, DM
    Zanetti, AR
    VACCINE, 2002, 20 (31-32) : 3720 - 3724
  • [46] Inhaled delivery of 23-valent pneumococcal polysaccharide vaccine does not result in enhanced pulmonary mucosal immunoglobulin responses
    Gordon, Stephen B.
    Malamba, Rose
    Mthunthama, Neema
    Jarman, Elizabeth R.
    Jambo, Kondwani
    Jere, Khuzwayo
    Zijlstra, Eduard E.
    Molyneux, Malcolm E.
    Dennis, John
    French, Neil
    VACCINE, 2008, 26 (42) : 5400 - 5406
  • [47] Failure to vaccinate or failure of vaccine? Effectiveness of the 23-valent pneumococcal polysaccharide vaccine program in Indigenous adults in the Northern Territory of Australia
    Moberley, S.
    Krause, V.
    Cook, H.
    Mulholland, K.
    Carapetis, J.
    Torzillo, P.
    Andrews, R.
    VACCINE, 2010, 28 (11) : 2296 - 2301
  • [48] Mechanisms of Immune-Related Long Non-Coding RNAs in Spleens of Mice Vaccinated with 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23)
    Zhu, Nan
    Zhang, Fan
    Zhou, Huan
    Ma, Wei
    Mao, Haiguang
    Wang, Mengting
    Ke, Zhijian
    Wang, Jinbo
    Qi, Lili
    VACCINES, 2023, 11 (03)
  • [49] Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
    Leach, Amanda J.
    Morris, Peter S.
    McCallum, Gabrielle B.
    Wilson, Cate A.
    Stubbs, Liz
    Beissbarth, Jemima
    Jacups, Susan
    Hare, Kim
    Smith-Vaughan, Heidi C.
    BMC INFECTIOUS DISEASES, 2009, 9
  • [50] A public health and budget impact analysis of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK
    Jiang, Yiling
    Gauthier, Aline
    Keeping, Sam
    Carroll, Stuart
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) : 901 - 911